China has banned the import of Illumina’s next-generation sequencing (NGS) sequencers as part of retaliatory measures against ...

Beijing banned imports of Illumina’s gene-sequencing machines in response to U.S. tariffs.

which analysts believe could significantly expand Illumina's Total (EPA:TTEF) Addressable Market (TAM) by making it easier for new Next-Generation Sequencing (NGS) customers to enter the market.

The San Diego company also lowered its financial guidance for 2025 in response to China’s import restrictions.

Illumina navigates competition and geopolitical risks with improved margins and strong cash flow. Read my analysis of ILMN ...

Illumina and next-gen sequencing (NGS) are synonymous. But to anyone paying attention, the company’s recent emphasis on multiomics has been hard to miss. Indeed, the company has launched both ...

Illumina has been barred from exporting its DNA sequencers to China, which closed | Illumina has been barred from exporting ...

Illumina Inc. (NASDAQ:ILMN), a leading provider of next-generation sequencing (NGS) technology with annual revenue of $4.37 billion, finds itself at a critical juncture as it navigates a shifting ...

Illumina is not banned from operating in the country and will continue to serve its existing customers, a company ...

Illumina has unveiled a new spatial technology that is designed to unlock further sequencing capabilities for researchers. Due for release in 2026, the US company’s technology for whole ...

Medical Device Network · JHVEPhoto via Shutterstock. China has banned the import of Illumina’s next-generation sequencing (NGS) sequencers as part of retaliatory measures against fresh tariffs ...